Glaxo Scientists ‘Live or Die’ With Project in Research Overhaul
This article is for subscribers only.
Six months ago, Roberto Solari talked eagerly about his research into the mechanisms that govern asthma. Now he must let someone else finish the job.
Solari, who until last month headed one of GlaxoSmithKline Plc’s targeted research units, is one of the casualties of the company’s new approach to drug discovery.